Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2026)

Top healthcare stocks in 2026 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

Xeris Biopharma Holdings (NASDAQ:XERS) is the #1 top healthcare stock out of 1049 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Xeris Biopharma Holdings (NASDAQ:XERS) is: Value: C, Growth: A, Momentum: A, Sentiment: A, Safety: C, Financials: B, and AI: B.

Xeris Biopharma Holdings (NASDAQ:XERS) has a Due Diligence Score of 39, which is 12 points higher than the healthcare sector average of 27. It passed 13 out of 33 due diligence checks and has average fundamentals. Xeris Biopharma Holdings has seen its stock return 105.05% over the past year, overperforming other healthcare stocks by 203 percentage points.

Xeris Biopharma Holdings has an average 1 year price target of $16.20, an upside of 2.34% from Xeris Biopharma Holdings's current stock price of $15.83.

Xeris Biopharma Holdings stock has a consensus Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Xeris Biopharma Holdings, 20% have issued a Strong Buy rating, 60% have issued a Buy, 20% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Regeneron Pharmaceuticals (NASDAQ:REGN) is the #2 top healthcare stock out of 1049 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Regeneron Pharmaceuticals (NASDAQ:REGN) is: Value: B, Growth: B, Momentum: C, Sentiment: A, Safety: B, Financials: B, and AI: B.

Regeneron Pharmaceuticals (NASDAQ:REGN) has a Due Diligence Score of 47, which is 20 points higher than the healthcare sector average of 27. It passed 18 out of 38 due diligence checks and has strong fundamentals. Regeneron Pharmaceuticals has seen its stock return 39.91% over the past year, overperforming other healthcare stocks by 138 percentage points.

Regeneron Pharmaceuticals has an average 1 year price target of $904.29, a downside of -1.28% from Regeneron Pharmaceuticals's current stock price of $916.06.

Regeneron Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 24 analysts covering Regeneron Pharmaceuticals, 58.33% have issued a Strong Buy rating, 8.33% have issued a Buy, 33.33% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Bausch Health Companies (NYSE:BHC) is the #3 top healthcare stock out of 1049 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Bausch Health Companies (NYSE:BHC) is: Value: A, Growth: B, Momentum: C, Sentiment: A, Safety: B, Financials: C, and AI: C.

Bausch Health Companies (NYSE:BHC) has a Due Diligence Score of 9, which is -18 points lower than the healthcare sector average of 27. Although this number is below the industry average, our proven quant model rates BHC as a "A".It passed 3 out of 33 due diligence checks and has weak fundamentals. Bausch Health Companies has seen its stock return 29.53% over the past year, overperforming other healthcare stocks by 128 percentage points.

Bausch Health Companies has an average 1 year price target of $9.00, an upside of 8.56% from Bausch Health Companies's current stock price of $8.29.

Bausch Health Companies stock has a consensus Hold recommendation according to Wall Street analysts. Of the 2 analysts covering Bausch Health Companies, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 80 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

Rallybio (NASDAQ:RLYB) has an annual dividend yield of 86.04%, which is 82 percentage points higher than the healthcare sector average of 3.55%.

Rallybio's dividend payout ratio of 0% indicates that its high dividend yield might not be sustainable for the long-term.

Cumberland Pharmaceuticals (NASDAQ:CPIX) has an annual dividend yield of 28.3%, which is 25 percentage points higher than the healthcare sector average of 3.55%.

Cumberland Pharmaceuticals's dividend payout ratio of -411% indicates that its high dividend yield might not be sustainable for the long-term.

Supernus (NASDAQ:SUPN) has an annual dividend yield of 28.28%, which is 25 percentage points higher than the healthcare sector average of 3.55%.

Supernus's dividend payout ratio of 0% indicates that its high dividend yield might not be sustainable for the long-term.

Healthcare stocks were down -0.26% in the last day, and up 2.67% over the last week. Exagen was the among the top losers in the healthcare sector, dropping -25.92% yesterday.

Exagen shares are trading lower after the company reported mixed Q3 financial results.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

Ironwood Pharmaceuticals (NASDAQ:IRWD) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Ironwood Pharmaceuticals has a valuation score of 86, which is 69 points higher than the healthcare sector average of 17. It passed 6 out of 7 valuation due diligence checks.

Ironwood Pharmaceuticals's stock has gained 90.12% in the past year. It has overperformed other stocks in the healthcare sector by 188 percentage points.

Harmony Biosciences Holdings (NASDAQ:HRMY) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 57, which is 40 points higher than the healthcare sector average of 17. It passed 4 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 5.44% in the past year. It has overperformed other stocks in the healthcare sector by 103 percentage points.

Embecta (NASDAQ:EMBC) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Embecta has a valuation score of 57, which is 40 points higher than the healthcare sector average of 17. It passed 4 out of 7 valuation due diligence checks.

Embecta's stock has dropped -52.96% in the past year. It has overperformed other stocks in the healthcare sector by 45 percentage points.

57.2% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 34.82% over the next year.

5.41% of healthcare stocks have a Zen Rating of A (Strong Buy), 13.77% of healthcare stocks are rated B (Buy), 47.1% are rated C (Hold), 25.35% are rated D (Sell), and 8.37% are rated F (Strong Sell).